Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: OTC vaginal contraceptives

This article was originally published in The Tan Sheet

Executive Summary

OTC vaginal contraceptives: American College of Nurse-Midwives tells FDA that removal of OTC status for vaginal contraceptives should not be undertaken "without strong evidence that these products pose a significant hazard to the health of their users." The Association for the Advancement of Health Care, in separate comments on FDA's proposal to require NDAs/ANDAs for OTC contraceptives, said FDA's proposal is "ill-advised" and will have a "negative impact" on availability of "affordable, reliable contraceptive options." Other industry and health professionals groups also have opposed the proposal ("The Tan Sheet" June 19, pp. 9-12)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel